Praxis Precision Medicines, Inc. PRAX Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s stock-based comp?
- Praxis Precision Medicines, Inc. (PRAX) reported stock-based comp of $17.11M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s stock-based comp changed year-over-year?
- Praxis Precision Medicines, Inc.'s stock-based comp increased by 94.8% year-over-year, from $8.79M to $17.11M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s stock-based comp has grown at a 10.6% compound annual growth rate (CAGR), from $22.69M to $33.94M.
- What does stock-based comp mean?
- The value of equity granted to employees as part of their compensation package.
- How do you interpret stock-based comp?
- An increase suggests higher reliance on equity to attract talent, which may lead to shareholder dilution.
- How does stock-based comp compare across companies?
- High in growth-stage technology and biotech companies as a way to preserve cash.